Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025284 · ClinicalTrials.gov registry record · Phase 2
A Study for Participants With Small-Cell Lung Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT01025284 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 64 participants.
The verdict
NCT01025284, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
Part A: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer. Part B: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer.
Interventions
- DRUG Granulocyte colony-stimulating factor (G-CSF)
- DRUG LY2523355
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01025284
The ClinicalTrials.gov registry entry for NCT01025284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Granulocyte colony-stimulating factor (G-CSF) is the first listed.
NCT01025284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01025284 about?
NCT01025284 is a clinical study titled "A Study for Participants With Small-Cell Lung Cancer". Part A: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer. Part B: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer.
What is the current status of trial NCT01025284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2009-12. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01025284?
The interventions under investigation include: Granulocyte colony-stimulating factor (G-CSF) (DRUG), LY2523355 (DRUG).
Who is sponsoring clinical trial NCT01025284?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.